Top entities: Celcuity, United States — Food and Drug Administration, Nasdaq, American Society of Clinical Oncology.

What category does this event fall under?

Business — classified as earnings call.

What is the sentiment of coverage?

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Aug 06, 2026. Coverage continues to evolve.

Business earnings call

Celcuity Q2 2026 Results Release

Q: When did this event occur?

First reported Aug 06, 2026; last updated Aug 06, 2026.

Q: What is the market impact?

General. The announcement is a routine scheduling notice for Celcuity's quarterly earnings release and conference call, which is unlikely to have a significant impact on the broader markets.

Analysis based on 6 articles · First reported Aug 06, 2026 · Last updated Aug 06, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The announcement is a routine scheduling notice for Celcuity's quarterly earnings release and conference call, which is unlikely to have a significant impact on the broader markets. Investors may watch for the company's financial results and any updates on its clinical programs, which could influence Celcuity's stock price.

Biotechnology

Event Summary

Celcuity Inc., a commercial-stage biotechnology company, announced that it will release its financial results for the second quarter of 2026 after market close on Thursday, August 13, 2026. Management will host a webcast and teleconference the same day at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a corporate update. The company highlighted its first FDA-approved product, REVTORPYK (gedatolisib), a pan-PI3K and mTORC1/2 inhibitor for the treatment of multiple solid tumor indications. Celcuity also provided updates on its clinical trials, including the Phase 3 VIKTORIA-1 trial that supported FDA approval of REVTORPYK, and the ongoing Phase 3 VIKTORIA-2 trial and Phase 1/2 CELC-G-201 trial. The announcement is a routine scheduling notice for the company's quarterly earnings release and conference call.

Key Actions

30 Celcuity announced participation

Entities Involved

stock

Celcuity

Celcuity is the company announcing its Q2 2026 financial results and hosting a conference call. The event is a routine corporate update, with potential impact on its stock depending on the results and any clinical trial updates.

Importance 100.0 Sentiment 0.0

govactor

United States — Food and Drug Administration

The FDA approved Celcuity's product REVTORPYK, which is mentioned in the announcement. The event does not involve new FDA actions, but the approval is part of the company's background.

Importance 20.0 Sentiment 0.0

exch

Nasdaq

Nasdaq is the stock exchange where Celcuity is listed (ticker: CELC). The event does not directly affect Nasdaq, but the company's performance may influence its stock price on the exchange.

Importance 10.0 Sentiment 0.0

ngo

American Society of Clinical Oncology

ASCO is mentioned as the venue where results from the VIKTORIA-1 trial were presented. The event does not involve new ASCO actions, but the presentation is part of the company's clinical development history.

Importance 10.0 Sentiment 0.0

Relationships

United States — Food and Drug Administration related ↔ Nasdaq

United States — Food and Drug Administration related ↔ American Society of Clinical Oncology

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard